Eltrombopag in Pediatric Severe Aplastic Anemia: Favorable Outcomes
Blood Journals Portfolio shared a post on X:
”Eltrombopag’s pharmacokinetics profile was similar to that seen in patients with immune thrombocytopenia, with no unexpected safety signals.”
Read the full article here.
Title: Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial
Authors: Akiko Shimamura, Alexey Maschan, Carolyn Bennett, Sujith Samarasinghe, Jason E. Farrar, Chi-kong Li, Nongnuch Sirachainan, Bunchoo Pongtanakul, Patcharee Komvilaisak, Ludmila Zubarovskaya, Jennifer A. Rothman, Kelly Walkovich, Taizo A. Nakano, Alison A. Bertuch, Anabela Ferrao, Rukhmi Bhat, Rabi Hanna, Kathleen Overholt, Jessica Boklan, Tze Fang Wong, Qinxia Wang, Patrick Urban, Brigitte Strahm, Winfred Wang, Adrianna Vlachos, David A. Williams
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM